Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH
dc.contributor.author | Konkle, Barbara | |
dc.contributor.author | Pierce, Glen | |
dc.contributor.author | Coffin, Donna | |
dc.contributor.author | Naccache, Mayss | |
dc.contributor.author | Clark, R. Cary | |
dc.contributor.author | George, Lindsey | |
dc.contributor.author | Iorio, Alfonso | |
dc.contributor.author | O’mahony, Brian | |
dc.contributor.author | Pipe, Steven | |
dc.contributor.author | Skinner, Mark | |
dc.contributor.author | Watson, Crystal | |
dc.contributor.author | Peyvandi, Flora | |
dc.contributor.author | Mahlangu, Johnny | |
dc.date.accessioned | 2020-11-04T16:00:49Z | |
dc.date.available | WITHHELD_13_MONTHS | |
dc.date.available | 2020-11-04T16:00:49Z | |
dc.date.issued | 2020-11 | |
dc.identifier.citation | Konkle, Barbara; Pierce, Glen; Coffin, Donna; Naccache, Mayss; Clark, R. Cary; George, Lindsey; Iorio, Alfonso; O’mahony, Brian ; Pipe, Steven; Skinner, Mark; Watson, Crystal; Peyvandi, Flora; Mahlangu, Johnny (2020). "Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH." Journal of Thrombosis and Haemostasis 18(11): 3074-3077. | |
dc.identifier.issn | 1538-7933 | |
dc.identifier.issn | 1538-7836 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/163440 | |
dc.description.abstract | BackgroundGene therapy for people with hemophilia (PWH) will soon become available outside current clinical trials. The World Federation of Hemophilia (WFH), in collaboration with International Society of Thrombosis and Hemostasis Scientific and Standardization Committee (ISTH SSC), the European Haemophilia Consortium (EHC), the US National Hemophilia Foundation (NHF), the American Thrombosis and Hemostasis Network (ATHN), industry gene therapy development partners and Regulatory liaisons have developed the Gene Therapy Registry (GTR), designed to collect long- term data on all PWH who receive hemophilia gene therapy.ObjectiveThe objectives of the GTR are to record the long- term safety and efficacy data post gene therapy infusion and to assess the changes in quality of life and burden of disease post- gene- therapy infusion.MethodsThe GTR is a prospective, observational, and longitudinal registry developed under the guidance of a multi- stakeholder GTR Steering Committee (GTR SC), composed of health care professionals, patient advocates, industry representatives, and regulatory agency liaisons. All PWH who receive gene therapy by clinical trial or commercial product will be invited to enrol in the registry through their hemophilia treatment centers (HTCs). The registry aims to recruit 100% of eligible post gene therapy PWH globally. Through an iterative process, and following the guidance of the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), the GTR SC has developed a core set of data to be collected on all patients post gene therapy.ResultsThe core data set includes demographic information, vector infusion details, safety, efficacy, quality of life and burden of disease.ConclusionsThe GTR is a global effort to ensure that long term safety and efficacy outcomes are recorded and analysed and rare adverse events, in a small patient population, are identified. Many unknowns on the long- term safety and efficacy of gene therapy for hemophilia may also be addressed. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | gene therapy | |
dc.subject.other | core data | |
dc.subject.other | hemophilia | |
dc.subject.other | registry | |
dc.subject.other | safety | |
dc.title | Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/163440/2/jth15023.pdf | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/163440/1/jth15023_am.pdf | en_US |
dc.identifier.doi | 10.1111/jth.15023 | |
dc.identifier.source | Journal of Thrombosis and Haemostasis | |
dc.identifier.citedreference | Butterfield JSS, Hege KM, Herzog RW, Kaczmarek R. A molecular revolution in the treatment of hemophilia. Mol Ther. 2019; 28 ( 4 ): 997 - 1015. | |
dc.identifier.citedreference | Nathwani AC. Gene therapy for hemophilia. Hematology. 2019; 2019: 1 - 8. | |
dc.identifier.citedreference | Pierce GF, Iorio A. Past, present and future of haemophilia gene therapy: from vectors and transgenes to known and unknown outcomes. Haemophilia. 2018; 24 ( Suppl 6 ): 60 - 67. | |
dc.identifier.citedreference | Peyvandi F, Makris M, Collins P, et al. Minimal dataset for post- registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2017; 15: 1878 - 1881. | |
dc.identifier.citedreference | Colella P, Ronzitti G, Mingozzi F. Emerging issues in AAV- mediated in vivo gene therapy. Mol Ther Methods Clin Dev. 2017; 8: 87 - 104. | |
dc.identifier.citedreference | George LA. Hemophilia gene therapy comes of age. Hematology. 2017; 2017: 587 - 594. | |
dc.identifier.citedreference | Konkle BA, Skinner M, Iorio A. Hemophilia trials in the twenty- first century: defining patient important outcomes. Res Pract Thromb Haemost. 2019; 3: 184 - 192. | |
dc.identifier.citedreference | Carmona G, Barnery L, Sewell J, et al. Correcting rare blood disorders using coagulation factors produced in vivo by shielded living therapeutics TM products. Blood. 2019; 134 ( Supplement 1 ): 2065. | |
dc.identifier.citedreference | Pasi KJ, Rangarajan S, Mitchell N, et al. Multiyear follow- up of AAV5- hFVIII- SQ gene therapy for hemophilia A. N Engl J Med. 2020; 382: 29 - 40. | |
dc.identifier.citedreference | Nguyen GN, Everett JK, Raymond H, et al. Long- term AAV- mediated factor VIII expression in nine hemophilia A dogs: a 10 year follow- up analysis on durability, safety and vector integration. Blood. 2019; 134 ( Suppl1 ): 611. | |
dc.identifier.citedreference | Chandler RJ, LaFave MC, Varshney GK, et al. Vector design influences hepatic genotoxicity after adeno- associated virus gene therapy. J Clin Invest. 2015; 125: 870 - 880. | |
dc.identifier.citedreference | Donsante A, Miller DG, Li Y, et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science. 2007; 317: 477. | |
dc.identifier.citedreference | Gil- Farina I, Fronza R, Kaeppel C, et al. Recombinant AAV integration is not associated with hepatic genotoxicity in nonhuman primates and patients. Mol Ther. 2016; 24: 1100 - 1105. | |
dc.identifier.citedreference | Batty P, Lillicrap D. Advances and challenges for hemophilia gene therapy. Hum Mol Genet. 2019; 28: R95 - R101. | |
dc.identifier.citedreference | Peyvandi F, Garagiola I. Clinical advances in gene therapy updates on clinical trials of gene therapy in haemophilia. Haemophilia. 2019; 25: 738 - 746. | |
dc.identifier.citedreference | Pharmacovigilance and epidemiology and regulatory and science management departments inspections HM, pharmacovigilance and committees and evaluation divisions. Report on Haemophilia Registries Workshop 8 June 2018. https://www.ema.europa.eu/en/documents/report/report- haemophilia- registries- workshop_en.pdf: European Medicines Agency; 2018: 1 - 23. | |
dc.identifier.citedreference | Long term follow- up after administration of human gene therapy products guidance for industry. https://www.fda.gov/regulatory- information/search- fda- guidance- documents/long- term- follow- after- administration- human- gene- therapy- products | |
dc.identifier.citedreference | Human gene therapy for hemophilia guidance for industry. https://www.fda.gov/regulatory- information/search- fda- guidance- documents/human- gene- therapy- hemophilia | |
dc.identifier.citedreference | Ray WA, Stein CM. Reform of drug regulation - beyond an independent drug- safety board. N Engl J Med. 2006; 354: 194 - 201. | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.